Braveheart Bio Files Amended Charter and Bylaws Ahead of IPO

What Happened
Braveheart Bio, Inc. announced that it filed a second amended and restated certificate of incorporation with the Delaware Secretary of State on August 7, 2026, effective immediately prior to the closing of its initial public offering (IPO). The company’s board and stockholders had previously approved the amended certificate and the second amended and restated bylaws, which became effective with the Registration Statement.

Key Details

• The amended certificate authorizes 500,000,000 shares of common stock.
• The company eliminated references to its prior series of preferred stock and instead authorized up to 10,000,000 shares of undesignated preferred stock that the board may issue in one or more series.
• The amended charter removes stockholders’ ability to act by written consent and to call special meetings of stockholders.
• The amended bylaws establish formal procedures for stockholder meetings, an advance-notice process for stockholder proposals and director nominations, and align with the updated certificate.

Why It Matters
These charter and bylaw changes set the legal framework for Braveheart’s governance and capital structure as a public company. The increased authorized common shares and the new undesignated preferred authorization give the company flexibility to issue equity or preferred securities in the future (which can affect dilution or rights). Removing written consent and special meeting rights and adding an advance-notice nomination process centralizes control over how and when stockholder actions and nominations can occur, which can affect how quickly investors can propose changes. Investors should note these structural rules when assessing ownership, voting rights, and potential future financings.